Kindly refer to attachment
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Glycols reported strong full-year results for FY2026 with standalone revenue of Rs 9,826 crore, up 8.7% from Rs 9,038 crore in the previous year. Standalone profit after tax (PAT) surged 56.5% to Rs 282 crore versus Rs 180 crore, driven by EBITDA growth of 32.4% to Rs 690 crore. The company declared an interim dividend of Rs 7.50 per share. The auditors issued an unmodified (clean) opinion on both standalone and consolidated financials. Key corporate actions include completion of a Rs 467 crore preferential equity allotment and ongoing NCLT approval for demerger of its Bio Pharma and Spirits & Biofuel businesses into separate listed entities. A non-recurring exceptional item of Rs 0.83 crore was recorded due to new labour code implementation.
The robust PAT growth of 56.5% and EBITDA margin expansion indicate strong operational efficiency, which is positive for shareholders. The clean audit opinion and progressing demerger scheme support confidence in corporate governance.